Strong preclinical anti-tumor activity with NRAS-mutant melanoma has also been shown after TANK-binding kinase 1 knockdown (TBK1-KD) plus MEKi (AZD6244/Selumetinib) [20]; ROCK inhibition plus trametinib [21]; ERβ activation plus trametinib [22]; as well as inhibition of Polo-like-kinase (PLK1) with MEKi (trametinib + volasertib) [23]. The gene discussed is TBK1; the disease is melanoma.